Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal modelsECCO'19 Copenhagen
Year: 2019
Authors: Jieun Shin
Epigenetics, Immunology, Macrophage, T cell
Files: 1
OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's diseaseECCO'19 Copenhagen
Year: 2019
Authors: Mathurin Fumery
Ustekinumab
Files: 1
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s diseaseECCO'19 Copenhagen
Year: 2019
Authors: Erwin Dreesen
Anti-TNF agents, Infliximab, Pharmacokinetics, Treat to target
Files: 1
OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancerECCO'19 Copenhagen
Year: 2019
Authors: Loris Riccardo Lopetuso
Ulcerative colitis, Colorectal cancer, Epithelial cell, Immunology, Mesenchymal cell
Files: 1
OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosisECCO'19 Copenhagen
Year: 2019
Authors: Kathleen Machiels
ANCA, ASCA, other serum markers, Colectomy, Ileo anal pouch procedure, Pouchitis, Proteomics
Files: 1
OP35: Endoscopic and Deep Remission at 1 Year Prevents Disease Progression in Early Crohn’s Disease: Long-Term Data from CALMECCO'19 Copenhagen
Year: 2019
Authors: Clara Yzet
Natural history, Crohn’s disease, Prognosis, Adalimumab, Treat to target, Mucosal healing, Outcome measures, Mucosal healing
Files: 1
OP37: Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFIECCO'19 Copenhagen
Year: 2019
Authors: William J. Sandborn
Ulcerative colitis, Ustekinumab
Files: 1
OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitisECCO'19 Copenhagen
Year: 2019
Authors: Geert D'Haens
Ulcerative colitis, Outcome measures, Commercial
Files: 1
Open surgery for IBD patients: Never?8th S-ECCO IBD Masterclass
Year: 2019
Authors: Fabrizio Michelassi
Laparoscopic surgery, Stricturoplasty, Post operative complications
Files: 1
Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agents17th IBD Intensive Advanced Course
Year: 2019
Authors: Dominik Bettenworth
Anti-TNF agents
Files: 1
Other small molecules (aprimelast/ozanimod)17th IBD Intensive Advanced Course
Year: 2019
Authors: Laurent Peyrin-Biroulet
Ozanimod, S1P receptor modulator
Files: 1
Other tumours in IBD4th H-ECCO IBD Masterclass
Year: 2019
Authors: Paula Borralho Nunes
Histology, Dysplasia, Lymphoma, IBD-associated cancer
Files: 1